BRIEF-Karyopharm completes enrollment in ongoing storm study; results expected mid-2016

* To report top-line data from phase 1b clinical trial of

selinexor in combination with some agents over next 18 months

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more